<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34783101</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1789</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuropathology : official journal of the Japanese Society of Neuropathology</Title><ISOAbbreviation>Neuropathology</ISOAbbreviation></Journal><ArticleTitle>Unexpected postmortem diagnoses in cases of clinically diagnosed amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>457</StartPage><EndPage>467</EndPage><MedlinePgn>457-467</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/neup.12744</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a motor neuron disease that is clinically and pathologically characterized by impairment of the upper and lower motor neurons. The clinical diagnosis of ALS is not always straightforward because of the lack of specific biomarkers and clinical heterogeneity. This review presents the clinical and pathological findings of four autopsied cases that had been diagnosed with ALS before death. These cases had demonstrated definite and progressive motor neuron signs and symptoms, whereas postmortem assessment revealed miscellaneous disorders, including fungal infection, paraneoplastic syndrome, and amyloidosis. Importantly, nonmotor neuron signs and symptoms, including seizures, extra-pyramidal signs, ocular movement disorders, sensory disturbance, and dysautonomia, had also been documented during the disease course of the cases in the present study. The ALS-unlike symptoms were indicative of the "true" diagnosis in each case when those symptoms were isolated from motor neuron signs/symptoms.</AbstractText><CopyrightInformation>&#xa9; 2021 Japanese Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riku</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6493-8976</Identifier><AffiliationInfo><Affiliation>Institute for &#x200a;Medical Science of Aging, Aichi Medical &#x200a;University, Nagakute, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for &#x200a;Medical Science of Aging, Aichi Medical &#x200a;University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Higashi Nagoya National Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamijo</LastName><ForeName>Mikiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chubu Rosai Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Keizo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kameyama</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chubu Rosai Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0059-3104</Identifier><AffiliationInfo><Affiliation>Institute for &#x200a;Medical Science of Aging, Aichi Medical &#x200a;University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Number JP20K16586</GrantID><Agency>JSPS KAKENHI</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Neuropathology</MedlineTA><NlmUniqueID>9606526</NlmUniqueID><ISSNLinking>0919-6544</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">amyloidosis</Keyword><Keyword MajorTopicYN="N">autopsy</Keyword><Keyword MajorTopicYN="N">cryptococcus</Keyword><Keyword MajorTopicYN="N">paraneoplastic syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34783101</ArticleId><ArticleId IdType="doi">10.1111/neup.12744</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299.</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC et al. Amyotrophic lateral sclerosis. Lancet 2011; 377: 942-955.</Citation></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T et al. TDP-43 proteinopathies: A new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2020; 92: 86-95.</Citation></Reference><Reference><Citation>Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: Experimental models and reality. Acta Neuropathol 2017; 133: 177-196.</Citation></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133.</Citation></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351: 602-611.</Citation></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208-1211.</Citation></Reference><Reference><Citation>Kwiatkowski TJ Jr, Bosco DA, Leclerc AL et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323: 1205-1208.</Citation></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D et al. Mutations in cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.</Citation></Reference><Reference><Citation>Josephs KA, Hodges JR, Snowden JS et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 2011; 122: 137-153.</Citation></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111-113.</Citation></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 2007; 114: 5-22.</Citation></Reference><Reference><Citation>Sampathu DM, Neumann M, Kwong LK et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006; 169: 1343-1352.</Citation></Reference><Reference><Citation>Riku Y, Watanabe H, Yoshida M et al. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. JAMA Neurol 2014; 71: 172-179.</Citation></Reference><Reference><Citation>Geser F, Martinez-Lage M, Robinson J et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009; 66: 180-189.</Citation></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2010; 107: 3858-3863.</Citation></Reference><Reference><Citation>Porta S, Xu Y, Restrepo CR et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun 2018; 9: 4220.</Citation></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20-38.</Citation></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011; 14: 459-468.</Citation></Reference><Reference><Citation>Klim JR, Williams LA, Limone F et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci 2019; 22: 167-179.</Citation></Reference><Reference><Citation>Iguchi Y, Eid L, Parent M et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain 2016; 139: 3187-3201.</Citation></Reference><Reference><Citation>Seilhean D, Cazeneuve C, Thuri&#xe8;s V et al. Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation. Acta Neuropathol 2009; 118: 561-573.</Citation></Reference><Reference><Citation>Riku Y, Duyckaerts C, Boluda S et al. Increased prevalence of granulovacuolar degeneration in C9orf72 mutation. Acta Neuropathol 2019; 138: 783-793.</Citation></Reference><Reference><Citation>Riku Y. Reappraisal of the anatomical spreading and propagation hypothesis about TDP-43 aggregation in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neuropathology 2020; 40: 426-435.</Citation></Reference><Reference><Citation>McCluskey L, Vandriel S, Elman L et al. ALS-Plus syndrome: Non-pyramidal features in a large ALS cohort. J Neurol Sci 2014; 345: 118-124.</Citation></Reference><Reference><Citation>Beardsley J, Sorrell TC, Chen SC. Central nervous system cryptococcal infections in non-HIV infected patients. J Fungi (Basel) 2019; 5: 71.</Citation></Reference><Reference><Citation>Singh N, Lortholary O, Dromer F et al. Central nervous system cryptococcosis in solid organ transplant recipients: Clinical relevance of abnormal neuroimaging findings. Transplantation 2008; 86: 647-651.</Citation></Reference><Reference><Citation>Aharon-Peretz J, Kliot D, Finkelstein R et al. Cryptococcal meningitis mimicking vascular dementia. Neurology 2004; 62: 2135.</Citation></Reference><Reference><Citation>Deb S, Walterfang M, Varghese D et al. Cryptococcal dementia in a patient with sarcoidosis. Med J Aust 2006; 184: 86-87.</Citation></Reference><Reference><Citation>Beardsley J, Wolbers M, Day JN, CryptoDex Investigators. Dexamethasone in cryptococcal meningitis. N Engl J Med 2016; 375: 189-190.</Citation></Reference><Reference><Citation>Gordon PH, Rowland LP, Younger DS et al. Lymphoproliferative disorders and motor neuron disease: An update. Neurology 1997; 48: 1671-1678.</Citation></Reference><Reference><Citation>Struck AF, Salamat S, Waclawik AJ. Motor neuron disease with selective degeneration of anterior horn cells associated with non-Hodgkin lymphoma. J Clin Neuromuscul Dis 2014; 16: 83-89.</Citation></Reference><Reference><Citation>Ogawa M, Nishie M, Kurahashi K, Kaimori M, Wakabayashi K. Anti-Hu associated paraneoplastic sensory neuronopathy with upper motor neurone involvement. J Neurol Neurosurg Psychiatry 2004; 75: 1051-1053.</Citation></Reference><Reference><Citation>Vogrig A, Joubert B, Maureille A et al. Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. J Neurol 2019; 266: 398-410.</Citation></Reference><Reference><Citation>Suzuki Y, Aizawa H, Sakashita K et al. Autopsy-proven case of paraneoplastic lower motor neuron disease with sensorimotor neuropathy due to Waldenstr&#xf6;m's macroglobulinemia. Neuropathology 2018; 38: 568-573.</Citation></Reference><Reference><Citation>M&#xe9;l&#xe9; N, Berzero G, Maisonobe T et al. Motor neuron disease of paraneoplastic origin: A rare but treatable condition. J Neurol 2018; 265: 1590-1599.</Citation></Reference><Reference><Citation>Cheli M, Dinoto A, Ridolfi M, Sartori A, Stokelj D, Manganotti P. Motor neuron disease as a treatment responsive paraneoplastic neurological syndrome in patient with small cell lung cancer, anti-Hu antibodies and limbic encephalitis. J Neurol Sci 2019; 400: 158-159.</Citation></Reference><Reference><Citation>Al-Bustani N, Simonson W, Marshall DA et al. Utility of paraneoplastic antibody testing in the diagnosis of motor neuron disease. J Clin Neuromuscul Dis 2015; 17: 63-68.</Citation></Reference><Reference><Citation>Verma A, Berger JR, Snodgrass S, Petito C. Motor neuron disease: A paraneoplastic process associated with anti-hu antibody and small-cell lung carcinoma. Ann Neurol 1996; 40: 112-116.</Citation></Reference><Reference><Citation>Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract Neurol 2013; 13: 153-164.</Citation></Reference><Reference><Citation>Quattrini A, Nemni R, Sferrazza B et al. Amyloid neuropathy simulating lower motor neuron disease. Neurology 1998; 51: 600-602.</Citation></Reference><Reference><Citation>Cappellari M, Cavallaro T, Ferrarini M et al. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 2011; 16: 119-129.</Citation></Reference><Reference><Citation>Kiernan MC, Guglielmi JM, Kaji R, Murray NM, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002; 125: 664-675.</Citation></Reference><Reference><Citation>Mills KR. Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome. Brain 2010; 133: 3458-3469.</Citation></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A et al. The Awaji criteria for diagnosis of ALS. Muscle Nerve 2011; 44: 456-457.</Citation></Reference><Reference><Citation>Grapperon AM, Attarian S. Disorders of motor neurons manifested by hyperactivity. Rev Neurol (Paris) 2017; 173: 345-351.</Citation></Reference><Reference><Citation>Ikeda K, Kinoshita M, Takamiya K et al. Bulbar palsy in senile onset familial amyloid polyneuropathy (30Val-&gt;Met): Transthyretin-amyloid deposits in the hypoglossal nerve root. Eur J Neurol 1998; 5: 211-214.</Citation></Reference><Reference><Citation>Nanri K, Utsumi H, Yamada M et al. Transthyretin Val 107 in a Japanese patient with familial amyloid polyneuropathy. J Neurol Sci 2002; 198: 93-96.</Citation></Reference><Reference><Citation>de Carvalho M, Scotto M, Swash M. Clinical patterns in progressive muscular atrophy (PMA): A prospective study. Amyotroph Lateral Scler 2007; 8: 296-299.</Citation></Reference><Reference><Citation>Ince PG, Evans J, Knopp M et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003; 60: 1252-1258.</Citation></Reference><Reference><Citation>Hu MT, Ellis CM, Al-Chalabi A, Leigh PN, Shaw CE. Flail arm syndrome: A distinctive variant of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1998; 65: 950-951.</Citation></Reference><Reference><Citation>Katz JS, Wolfe GI, Andersson PB et al. Brachial amyotrophic diplegia: A slowly progressive motor neuron disorder. Neurology 1999; 53: 1071-1076.</Citation></Reference><Reference><Citation>Keegan JJ. The cause of dissociated motor loss in the upper extremity with cervical spondylosis. J Neurosurg 1965; 23: 528-536.</Citation></Reference><Reference><Citation>Swash M. Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2012; 83: 659-662.</Citation></Reference><Reference><Citation>Miller TM, Johnston SC. Should the Babinski sign be part of the routine neurologic examination? Neurology 2005; 65: 1165-1168.</Citation></Reference><Reference><Citation>Kuwabara S, Sonoo M, Komori T et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: Frequency, extent, and specificity. Muscle Nerve 2008; 37: 426-430.</Citation></Reference><Reference><Citation>Wilbourn AJ. The "split hand syndrome". Muscle Nerve 2000; 23: 138.</Citation></Reference><Reference><Citation>Kameyama T, Ando T. Amyotrophic lateral sclerosis. Orthop Surg Traumatol 2014; 57: 1661-1670. (In Japanese.).</Citation></Reference><Reference><Citation>Khalaf R, Martin S, Ellis C et al. Relative preservation of triceps over biceps strength in upper limb-onset ALS: The &#x2018;split elbow&#x2019;. J Neurol Neurosurg Psychiatry 2019; 90: 730-733.</Citation></Reference><Reference><Citation>Simon NG, Lee M, Bae JS et al. Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. J Neurol 2015; 262: 1424-1432.</Citation></Reference><Reference><Citation>van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S. Pathophysiology and diagnosis of ALS: Insights from advances in neurophysiological techniques. Int J Mol Sci 2019; 20: 2818.</Citation></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. Amyotrophic lateral sclerosis-a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9: 708-714.</Citation></Reference><Reference><Citation>Senda J, Atsuta N, Watanabe H et al. Structural MRI correlates of amyotrophic lateral sclerosis progression. J Neurol Neurosurg Psychiatry 2017; 88: 901-907.</Citation></Reference><Reference><Citation>de Carvalho M, Swash M. Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: A six-month longitudinal study. Muscle Nerve 2010; 41: 208-211.</Citation></Reference><Reference><Citation>Tokimura R, Murakami T, Ugawa Y. Central motor conduction time reveals upper motor neuron involvement masked by lower motor neuron impairment in a significant portion of patients with amyotrophic lateral sclerosis. Clin Neurophysiol 2020; 131: 1896-1901.</Citation></Reference><Reference><Citation>Riku Y, Atsuta N, Yoshida M et al. Differential motor neuron involvement in progressive muscular atrophy: A comparative study with amyotrophic lateral sclerosis. BMJ Open 2014; 4: e005213.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>